Effect of tocopherol supplementation on serum 8-epi-prostaglandin F2 alpha and adiponectin concentrations, and mRNA expression of PPARγ and related genes in ovine placenta and uterus

Theriogenology

Volumn 76, Issue 3, 2011, Pages 482-491

  Kasimanickam, R K ^a   Kasimanickam, V R ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Adiponectin; ADIPQ; Isoprostane; PPAR ; Sheep; Vitamin E

Indexed keywords

8 EPI PROSTAGLANDIN F2ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; ADIPONECTIN; DRUG DERIVATIVE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN F2 ALPHA; SOMATOMEDIN B; SOMATOMEDIN C; TOCOPHEROL;

ANIMAL; ARTICLE; BLOOD; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PLACENTA; PREGNANCY; SHEEP; UTERUS;

ADIPONECTIN; ANIMALS; DINOPROST; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; PLACENTA; PPAR GAMMA; PREGNANCY; RNA, MESSENGER; SHEEP; TOCOPHEROLS; UTERUS;

OVIS; OVIS ARIES;

EID: 79959825067     PISSN: 0093691X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.theriogenology.2011.02.025     Document Type: Article

References (55)

1. Briana D.D., Malamitsi-Puchner A. The role of adipocytokines in fetal growth. Ann NY Acad Sci 2010, 1205:82-87.
2. Pajvani U.B., Du X., Combs T.P., Berg A.H., Rajala M.W., Schulthess T., Engel J., Brownlee M., Scherer P.E. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 2003, 278:9073-9085.
3. Fruebis J., Tsao T.S., Javorschi S., Ebbets-Reed D., Erickson M.R., Yen F.T., Bihain B.E., Lodish H.F. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001, 98:2005-2010.
4. Tsao T.S., Tomas E., Murrey H.E., Hug C., Lee D.H., Ruderman N.B., Heuser J.E., Lodish H.F. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem 2003, 278:50810-50817.
5. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., Sugiyama T., Miyagishi M., Hara K., Tsunoda M., Murakami K., Ohteki T., Uchida S., Takekawa S., Waki H., Tsuno N.H., Shibata Y., Terauchi Y., Froguel P., Tobe K., Koyasu S., Taira K., Kitamura T., Shimizu T., Nagai R., Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-976.
6. Chen J., Tan B., Karteris E., Zervou S., Digby J., Hillhouse E.W., Vatish M., Randeva H.S. Secretion of adiponectin by human placenta: differential modulation of adiponectin and its receptors by cytokines. Diabetologia 2006, 49:1292-1302.
7. Caminos J.E., Nogueiras R., Gallego R., Bravo S., Tovar S., García-Caballero T., Casanueva F.F., Diéguez C. Expression and regulation of adiponectin and receptor in human and rat placenta. J Clin Endocrinol Metab 2005, 90:4276-4286.
8. Madamanchi N.R., Vendrov A., Runge M.S. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005, 25:29-38.
9. Li R., Wang W.Q., Zhang H., Yang X., Fan Q., Christopher T.A., Lopez B.L., Tao L., Goldstein B.J., Gao F., Ma X.L. Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity. Am J Physiol Endocrinol Metab 2007, 293:E1703-E1708.
10. Urakawa H., Katsuki A., Sumida Y., Gabazza E.C., Murashima S., Morioka K., Maruyama N., Kitagawa N., Tanaka T., Hori Y., Nakatani K., Yano Y., Adachi Y. Oxidative stress is associated with adiposity and insulin resistance in men. J Clin Endocrinol Meta 2003, 88:4673-4676.
11. Morrow J.D. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Bio 2005, 25:279-286.
12. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., Nakayama O., Makishima M., Matsuda M., Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Inves 2004, 114:1752-1761.
13. Schwedhelm E., Bartling A., Lenzen H., Tsikas D., Maas R., Brümmer J., Gutzki F.M., Berger J., Frölich J.C., Böger R.H. Urinary 8-isoprostaglandin F2α as a risk marker of in patients with coronary artery disease: a matched case-control study. Circulation 2004, 109:843-848.
14. Takahashi K., Nammour T.M., Fukunaga M., Ebert J., Morrow J.D., Roberts L.J., Hoover R.L., Badr K.F. Glomerular actions of a free-radical-generated novel prostaglandin, 8-epi-prostaglandin F2α in the rat: evidence for interaction with thromboxane A2 receptors. J Clin Invest 1992, 90:136-141.
15. Minuz P., Andrioli G., Degan M., Gaino S., Ortolani R., Tommasoli R., Zuliani V., Lechi A., Lechi C. The F2-isoprostane 8-epi-prostaglandin F2α increases platelet adhesion and reduces antiadhesive and antiaggregatory effects of NO. Arteriolscler Thromb Vasc Biol 1998, 18:1248-1256.
16. Scholz H., Aukrust P., Damås J.K., Tonstad S., Sagen E.L., Kolset S.O., Hall C., Yndestad A., Halvorsen B. 8-isoprostane increases scavenger receptor A and matrix metalloproteinase activity in THP-1 macrophages, resulting in long-lived foam cells. Eur J Clin Invest 2004, 34:451-458.
17. Soares A.F., Guichardant M., Cozzone D., Bernoud-Hubac N., Bouzaïdi-Tiali N., Lagarde M., Gélo'n A. Effects of oxidative stress on adiponectin secretion and lactate production in 3T3-L1 adipocytes. Free Radic Biol Med 2005, 38:882-889.
18. Nakanishi S., Yamane K., Kamei N., Nojima H., Okubo M., Kohno N.A. Protective effect of adiponectin against oxidative stress in Japanese Americans: the association between adiponectin or leptin and urinary isoprostane. Metabolism 2004, 54:194-199.
19. Dav G., Ciabattoni G., Consoli A., Mezzetti A., Falco A., Santarone S., Pennese E., Vitacolonna E., Bucciarelli T., Costantini F., Capani F., Patrono C. In vivo formation of 8-iso-prostaglandin F2α and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999, 99:224-229.
20. Manning P.J., Sutherland W.H., Walker R.J., Williams S.M., De Jong S.A., Ryalls A.R., Berry E.A. Effect of high-dose vitamin E on insulin resistance and associated parameters in overweight subjects. Diabetes Care 2004, 27:2166-2171.
21. Barak Y., Sadovsky Y., Shalom-Barak T. PPAR signaling in placental development and function. PPAR Res 2008, 2008:142082.
22. Evans R.M., Barish G.D., Wang Y.X. (2004) PPARs and the complex journey to obesity. Nat Med 2004, 10:355-361.
23. Glass C.K. Going nuclear in metabolic and cardiovascular disease. J Clin Invest 2006, 116:556-560.
24. Straus D.S., Glass C.K. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 2007, 28:551-558.
25. Walczak R., Tontonoz P. PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism. J Lipid Res 2002, 43:177-186.
26. Gelman L., Fruchart J.-C., Auwerx J. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci 1999, 55:932-943.
27. Moller D.E., Berger J.P. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes Relat Metab Disord 2003, 27(Suppl 3):S17-S21.
28. Berger J., Moller D.E. The mechanisms of action of PPARs. Annu Rev Med 2002, 53:409-435.
29. Barak Y., Nelson M.C., Ong E.S., Jones Y.Z., Ruiz-Lozano P., Chien K.R., Koder A., Evans R.M. PPARgamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999, 4:585-595.
30. Tarrade A., Schoonjans K., Guibourdenche J., Bidart J.M., Vidaud M., Auwerx J., Rochette-Eglyo C., Evain-Brion D. PPARgamma/RXR alpha heterodimers are involved in human CG beta synthesis and human trophoblast differentiation. Endocrinology 2001, 142:4504-4514.
31. Yamauchi T., Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes 2008, 32(Suppl 7):S13-S18.
32. Kasimanickam R.K., Kasimanickam V.R., Rodriguez J.S., Pelzer K.D., Sponenberg P.D., Thatcher C.D. Tocopherol induced angiogenesis in placental vascular network in late pregnant ewes. Reprod Biol Endocrinol 2010, 12;8:86.
33. Braekke K., Harsem N.K., Staff A.C. Oxidative stress and antioxidant status in fetal circulation in preeclampsia. Pediatr Res 2006, 60:560-564.
34. Ishihara O., Hayashi M., Osawa H., Kobayashi K., Takeda S., Vessby B., Basu S. Isoprostanes, prostaglandins and tocopherols in pre-eclampsia, normal pregnancy and non-pregnancy. Free Radic Res 2004, 38:913-918.
35. Palm M., Axelsson O., Wernroth L., Basu S. F(2)-isoprostanes, tocopherols and normal pregnancy. Free Radic Res 2009, 43:546-552.
36. Chappell L.C., Seed P.T., Kelly F.J., Briley A., Hunt B.J., Charnock-Jones D.S., Mallet A., Poston L. Vitamin C and E supplementation in women at risk of preeclampsia is associated with changes in indices of oxidative stress and placental function. Am J Obstet Gynecol 2002, 187:777-784.
37. Longini M., Perrone S., Kenanidis A., Vezzosi P., Marzocchi B., Petraglia F., Centini G., Buonocore G. Isoprostanes in amniotic fluid: a predictive marker for fetal growth restriction in pregnancy. Free Radic Biol Med 2005, 38:1537-1541.
38. Shen X.H., Tang Q.Y., Huang J., Cai W. Vitamin E regulates adipocytokine expression in a rat model of dietary-induced obesity. Exp Biol Med (Maywood) 2010, 235:47-51.
39. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., Hotta K., Nishida M., Takahashi M., Muraguchi M., Ohmoto Y., Nakamura T., Yamashita S., Funahashi T., Matsuzawa Y. Adiponectin, an adipocyte- derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296-1301.
40. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., Nakayama O., Makishima M., Matsuda M., Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114:1752-1761.
41. Venugopal S., Devaraj S., Yang T., Jialal I. a-Tocopherol decreases superoxide anion release in human monocytes under hyperglycemic conditions via inhibition of protein kinase C. Diabetes 2002, 51:3049-3054.
42. Calvisi D.F., Ladu S., Hironaka K., Factor V.M., Thorgeirson S.S. Vitamin E down-modulates iNOS and NADPH oxidase in c-Myc/TGF-a transgenic mouse model of liver cancer. J Hepatol 2004, 41:815-822.
43. Nakanishi S., Yamane K., Kamei N., Nojima H., Okubo M., Kohno N. A protective effect of adiponectin against oxidative stress in Japanese Americans: the association between adiponectin or leptin and urinary isoprostane. Metab Clin Exp 2005, 54:194-199.
44. Tie Weiwei, Yu Haiyan, Chen Juan, Wang Xiaodong, Chen Weibo, Zhou Rong Expressions of adiponectin receptors in placenta and their correlation with preeclampsia. Reprod Sci 2009, 16:676-684.
45. Meller M., Qiu C., Vadachkoria S., Abetew D.F., Luthy D.A., Williams M.A. Changes in placental adipocytokine gene expression associated with gestational diabetes mellitus. Physiol Res 2006, 55:501-512.
46. Mise H., Sagawa N., Matsumoto T., Yura S., Nanno H., Itoh H., Mori T., Masuzaki H., Hosoda K., Ogawa Y., Nakao K. Augmented placental production of leptin in preeclampsia: possible involvement of placental hypoxia. J Clin Endocrinol Metab 1998, 83:3225-3229.
47. Traber M.G., Burton G.W., Hughes L., Ingold K.U., Hidaka H., Malloy M., Kane J., Hyams J., Kayden H.J. Discrimination between forms of vitamin E by humans with and without genetic abnormalities of lipoprotein metabolism. J Lipid Res 1992, 33:1171-1182.
48. Schaiff W.T., Carlson M.G., Smith S.D., Levy R., Nelson D.M., Sadovsky Y. Peroxisome proliferator-activated receptor-gamma modulates differentiation of human trophoblast in a ligand-specific manner. J Clin Endocrinol Metab 2000, 85:3874-3881.
49. Tarrade A., Schoonjans K., Pavan L., Auwerx J., Rochette-Egly C., Evain-Brion D., Fournier T. PPARgamma/RXRalpha heterodimers control human trophoblast invasion. J Clin Endocrinol Metab 2001, 86:5017-5024.
50. Tontonoz P., Hu E., Graves R.A., Budavari A.I., Spiegelman B.M. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994, 8:1224-1234.
51. Papi A., Rocchi P., Ferreri A.M., Orlandi M. RXRgamma and PPARgamma ligands in combination to inhibit proliferation and invasiveness in colon cancer cells. Cancer Lett 2010, 297:65-74.
52. Fournier T., Thérond P., Handschuh K., Tsatsaris V., Evain-Brion D. PPARgamma and early human placental development. Curr Med Chem 2008, 15:3011-3024.
53. Shalom-Barak T., Nicholas J.M., Wang Y., Zhang X., Ong E.S., Young T.H., Gendler S.J., Evans R.M., Barak Y. Peroxisome proliferator-activated receptor γ controls muc1 transcription in trophoblasts. Mol Cell Biol 2004, 24:10661-10669.
54. Schaiff W.T., Knapp F.F., Barak Y., Biron-Shental T., Nelson D.M., Sadovsky Y. Ligand-activated peroxisome proliferator activated receptor γ alters placental morphology and placental fatty acid uptake in mice. Endocrinology 2007, 148:3625-3634.
55. Muhlhausler B.S., Duffield J.A., McMillen I.C. Increased maternal nutrition stimulates Peroxisome Proliferator Activated Receptor-γ, adiponectin, and leptin messenger Ribonucleic Acid expression in adipose tissue before birth. Endocrinology 2007, 148:878-885. J. A.